Eastwood Bio-Medical Canada Inc

Eastwood Bio-Medical Canada Inc

EBM · V · Healthcare / Biotechnology

1.75CAD+0.05 (+2.94%)

Price History

Full chart

Market Stats

Previous Close1.70
Open1.61
Day Range1.61 – 1.75
52-Week Range0.435 – 2.06
Volume2.39K
Market Cap137.77M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta0.35
50-Day Avg1.62
200-Day Avg0.9957

About

Eastwood Bio-Medical Canada Inc. markets, develops research, and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. The company distributes Eleotin, which provides natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. It also offers Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for bones, teeth, and health; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. In addition, the company provides Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. It has a joint research agreement with BioNexus Inc. to build a platform that applies artificial intelligence to herbal ingredient prescription data in order to identify natural drug and functional food product candidates. The company was incorporated in 2010 and is based in Richmond, Canada. Eastwood Bio-Medical Canada Inc. operates as a subsidiary of Eastwood Bio-Medical Research Inc.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Youngsoo Kim
  • Employees0
  • Headquarters4871 Shell Road, Richmond, BC, Canada, V6X 3Z6, Canada
  • Websitehttps://eleotin.ca

Leadership

  • Dr. Youngsoo KimFounder, CEO & Director
  • Ms. Yunji Kim Esq.President, CFO, Corporate Secretary & Director · b. 1982

Financials

Income Statement

Currency: CAD2013-10-312014-10-312015-10-312016-10-312017-10-312018-10-312019-10-312020-10-312021-10-312022-10-312023-10-312024-10-312025-10-31
Total Revenue580.32K461.51K1.19M463.93K479.73K743.97K1.29M718.34K981.05K1.30M867.94K702.08K782.08K
Growth (%)--20.47%+157.00%-60.89%+3.40%+55.08%+73.78%-44.44%+36.57%+32.49%-33.22%-19.11%+11.40%
Cost of Revenue172.03K217.44K816.51K263.45K274.49K361.30K727.81K505.03K522.68K397.02K427.42K247.69K231.09K
Gross Profit408.29K244.07K369.58K200.48K205.24K382.68K565.09K213.31K458.37K902.74K440.51K454.39K550.99K
Gross Margin70.36%52.88%31.16%43.21%42.78%51.44%43.71%29.69%46.72%69.45%50.75%64.72%70.45%
Operating Expense551.92K750.14K657.97K707.97K791.44K948.60K1.13M1.05M1.05M1.03M946.55K892.09K843.32K
Operating Income-143.62K-506.07K-288.38K-507.50K-586.21K-565.93K-563.79K-838.66K-590.89K-128.76K-506.04K-437.70K-292.33K
Operating Margin-24.75%-109.66%-24.31%-109.39%-122.20%-76.07%-43.61%-116.75%-60.23%-9.91%-58.30%-62.34%-37.38%
EBITDA-143.62K-490.12K-272.85K-501.46K-591.69K-165.15K-517.79K-732.91K-485.59K-21.91K-398.19K-330.16K-247.37K
EBITDA Margin-24.75%-106.20%-23.00%-108.09%-123.34%-22.20%-40.05%-102.03%-49.50%-1.69%-45.88%-47.03%-31.63%
Net Income-139.28K-519.10K-260.38K-468.48K-489.62K-861.98K-579.68K-860.03K-611.34K-160.58K-546.60K-455.87K-332.77K
Net Income Margin-24.00%-112.48%-21.95%-100.98%-102.06%-115.86%-44.84%-119.73%-62.31%-12.35%-62.98%-64.93%-42.55%
Interest Expense3.54K2.18K1.83K1.07K1.35K77.13K5.32K2.37K2.79K10.71K28.16K6.29K-
Interest Expense % of Total Revenue0.61%0.47%0.15%0.23%0.28%10.37%0.41%0.33%0.28%0.82%3.24%0.90%-

Balance Sheet

Currency: CAD2013-10-312014-10-312015-10-312016-10-312017-10-312018-10-312019-10-312020-10-312021-10-312022-10-312023-10-312024-10-312025-10-31
Total Assets3.71M4.08M3.82M3.24M2.82M2.25M1.65M933.38K691.12K584.53K489.14K274.29K218.77K
Total Liabilities3.92M89.19K98.08K35.56K55.76K361.41K335.73K474.10K835.44K878.73K1.33M1.57M1.85M
Total Equity-208.29K3.99M3.73M3.21M2.76M1.89M1.31M459.27K-144.32K-294.20K-840.80K-1.30M-1.63M
Cash5.25K2.54M2.78M1.53M1.27M826.59K625.35K122.66K20.87K39.84K18.45K017.70K
Total Debt-------23.21K31.35K62.25K23.08K--
Net Debt-5.25K-2.54M-2.78M-1.53M-1.27M-826.59K-625.35K-99.44K10.48K22.41K4.63K79.61K60.30K

Cash Flow

Currency: CAD2013-10-312014-10-312015-10-312016-10-312017-10-312018-10-312019-10-312020-10-312021-10-312022-10-312023-10-312024-10-312025-10-31
Operating Cash Flow-252.88K1.58M-270.51K-306.58K-355.28K-454.79K-178.13K-542.69K-116.21K-4.29K-16.89K-15.22K19.30K
Investing Cash Flow113.62K113.62K513.48K-940.00K-1.12K-23.11K-23.11K-5.57K-5.57K-3.00K---
Financing Cash Flow257.65K839.97K-2.70K-1.44M97.55K10.00K40.00K40.00K20.00K26.27K-4.50K-4.62K-211
Capital Expenditure00023.11K23.11K23.11K23.11K5.57K5.57K3.00K000
Free Cash Flow-252.88K1.58M-270.51K-306.58K-355.28K-454.79K-201.24K-542.69K-121.79K-7.30K-16.89K-15.22K19.30K
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%112.97%100.00%104.80%169.98%100.00%100.00%100.00%

Earnings

Report DateJan 31, 2017Apr 30, 2017Jul 31, 2017Oct 31, 2017Jan 31, 2018Apr 30, 2018Jul 31, 2018Oct 31, 2018Jan 31, 2019Apr 30, 2019Jul 31, 2019Oct 31, 2019Mar 30, 2020Jun 30, 2020Sep 30, 2020Jan 20, 2021Mar 30, 2021Jun 29, 2021Sep 28, 2021Oct 31, 2021Apr 1, 2022Jun 29, 2022Sep 29, 2022Oct 31, 2022Mar 31, 2023Jun 30, 2023Sep 28, 2026Mar 1, 2027
EPS Estimate----------------------------
EPS Actual-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.000.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00--
Surprise----------------------------
Timing--------------------Pre-marketAfter-hoursAfter-hours-After-hoursPre-marketAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap137.77M
Enterprise Value126.12M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales169.65
Price / Book2961.32
EPS-0.01
Book Value-0.026
Revenue (TTM)812.12K
Gross Profit (TTM)569.54K
EBITDA-147.53K
Profit Margin-28.51%
Operating Margin-41.41%
Return on Equity-747.16%
Return on Assets-47.20%
Shares Outstanding68.89M
Shares Float21.16M
Beta0.35
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%